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Abstract
Background: To determine the effects of noninvasive mechanical ventilation (NIV) compared with invasive mechanical
ventilation (IMV) as the initial mechanical ventilation on clinical outcomes when used for treatment of acute respiratory
failure (ARF) in immunocompromised patients.
Methods: We searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Chinese
Biomedical Literature Database (CBM) and other databases. Subgroup analyses by disease severity and causes of
immunodeficiency were also conducted.
Results: Thirteen observational studies with a total of 2552 patients were included. Compared to IMV, NIV was shown
to significantly reduce in-hospital mortality (OR 0.43, 95 % CI 0.23 to 0.80, P value = 0.007) and 30-day mortality (OR 0.34,
95 % CI 0.20 to 0.61, P value < 0.0001) in overall analysis. Subgroup analysis showed NIV had great advantage over IMV
for less severe, AIDS, BMT and hematological malignancies patients in reducing mortality and duration of ICU stay.
Conclusions: The overall evidence we obtained shows NIV does more benefits or at least no harm to ARF patients with
certain causes of immunodeficiency or who are less severe.
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Background
The immunocompromised condition is defined as a state
of subnormal immune response of the host to a foreign
antigen, which could be congenital (primary) or acquired
(secondary) [1], with primary immunodeficiencies caused
by gene mutations and secondary caused by malignancy,
chemotherapies of malignancy, malnutrition, aging, viral
infection, immunosuppressive medication for treatment of
a variety of disorders such as autoimmune disease and
organ transplantation. The number of immunocomprom-
ised patients has increased dramatically over recent de-
cades [2]. In spite of better antimicrobial agents and
preventive measures, infections continue to be one of the
most frequent complications in immunocompromised pa-
tients and have a high mortality rate of 30 to 90 % [2], with
the highest when acute respiratory failure (ARF) occurs.
Thus, early diagnosis and proper intervention are essential
for better outcomes. Noninvasive mechanical ventilation
(NIV) and invasive mechanical ventilation (IMV) are two
approaches for providing supplemental oxygen for patients
with relatively severe ARF. NIV has gained more and more
popularity since its first application in 1980s [3], and is
now widely accepted as a first-line intervention for certain
forms of ARF, including acute exacerbation of chronic ob-
structive pulmonary disease (AECOPD) and cardiogenic
pulmonary edema [4–14].
Although the use of NIV as a first-line strategy for im-
munocompromised patients with acute respiratory failure
was recommended by Canadian Critical Care Society Non-
invasive Ventilation Guidelines Group(Grade 2B: weak
recommendation and moderate evidence quality) [11], re-
cent studies showed noninvasive ventilation might not be
the appropriate choice for all immunocompromised pa-
tients [15–17]. The choice of NIV versus IMV for im-
munocompromised patients, especially for relatively severe
ARF, is still under debate. On the other hand, there are
studies indicating that the use of NIV as the initial treat-
ment for certain population may delay intubation, which
may increase mortality and cost of health care [17–20].
Identifying the proper candidates and evidence for the ef-
fect of NIV is of great importance for better outcome of
immunocompromised patients with ARF. This review will
provide a systematic review of the evidences to determine
the effects of NIV compared to IMV on clinical outcomes




We searched the following databases (Additional file 1):
PubMed, EMBASE, the Cochrane Central Register of Con-
trolled Trials (CENTRAL), and Chinese Biomedical Litera-
ture Database (CBM, in Chinese). We also searched other
resources including Web of Science (WOS), National
technical information service conference proceedings
(NTIS), Open Grey (OG), and conference proceedings
for relevant abstracts, online clinical trial registers for on-
going and recently completed studies including Controlled
Clinical Trials (http://www.controlled-trials.com/), govern-
ment registries (http://www.clinicaltrials.gov), and World
Health Organization registries (http://www.who.int/
trialsearch/). There was no study type, language, date,
or publication type restrictions. We searched the bibliog-
raphy of all included studies and requested original data
from the primary authors when necessary. The most re-
cent search was conducted on April 15th, 2016.
Inclusion criteria
We included randomized controlled trials (RCTs) and
non-RCTs. We accepted the definition of acute respiratory
failure as the state when ratio of the partial pressure of ar-
terial oxygen to the fraction of inspired oxygen (PaO2/
FiO2) ≤ 300 mmHg. For studies enrolling patients with
other causes for mechanical ventilation, we stipulated that
a minimum of 85 % of patients must have ARF to meet
the inclusion criteria. Alternatively, patients were consid-
ered as immunocompromised when clinically diagnosed
as: 1) HIV-infected individuals (with or without acquired
immune deficiency syndrome, AIDS), 2) individuals on
immunosuppressive therapy (e.g., cytotoxic agents, gluco-
corticoids, etc.), 3) transplantation individuals (i.e., solid
organ transplantation or bone marrow transplantation), 4)
hematologic cancers, 5) certain trauma or surgery (splen-
ectomy), 6) secondary to metabolic diseases (e.g., malnu-
trition, noncontrolled diabetes, uremia). The intervention
group included patients who received NIV as the initial
mechanical ventilation technique, in addition to standard
medical care, irrespective of whether IMV was also used
later during the hospital stay. The control group included
patients who received IMV as the initial MV technique.
Patients with absolute contraindications of NIV including
respiratory arrest and inability to fit the mask, or with
underlying pathologies where NIV and IMV is both con-
traindicated, such as facial trauma, were excluded. We in-
cluded studies in which at least one of the review-defined
outcomes was identified. The primary outcomes were
all-cause mortality, including mortality in hospital or
intensive care unit (ICU), and 30-day mortality after ICU
admission. The secondary outcomes included duration of
hospitalization and ICU stay, nosocomial infections, and
duration of mechanical ventilation.
Data extraction and study quality
Two authors (JH and YM) independently assessed studies
for inclusion retrieved from electronic searches and other
resources and extracted data from the included studies. In
cases of ambiguity or insufficient data, we requested add-
itional information from study authors. Disagreements were
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ultimately resolved by a third author (YL). We used a
standardised data extraction form to collect the following
data: 1) General information: study ID, title, authors,
source, language and year of publication, country, and
source of funding. 2) Study characteristics: study type,
hospital settings, and dates of study. 3) Participants: age,
sex, diagnosis standard and cause of ARF and the immune
status, sample size, baseline physiological variables includ-
ing Acute Physiology and Chronic Health Evaluation
(APACHE II) scores, Simplified Acute Physiology Scores
(SAPS II) [21] and details of respiratory state on admis-
sion. 4) Interventions: intervention used in each group
and number of each group; indications, contraindications,
settings and duration of intervention. 5) Outcomes: mor-
tality (in ICU, in hospital and 30-day), duration of
mechanical ventilation, ICU stay and hospitalization,
number of participants with development of major com-
plications or nosocomial infections, numbers experi-
encing each outcome, and information of follow-up. 6)
Methodological quality: items in the Cochrane Collabora-
tion’s tool [22] and Newcastle Ottawa Scale for assessing
risk of bias (Additional file 1) [23].
Two review authors (TW, LXZ) independently assessed
the risks of bias in included studies. We used the adapted
Newcastle Ottawa Scale to assess the risks of bias, in-
cluding selection, comparability and outcome/expos-
ure (Additional file 1) [23]. We also explored other risks
of bias such as reporting bias. We then analyzed the qual-
ity of evidence following the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
methodology [24, 25].
Statistical analysis
We used random-effect models throughout the analysis to
take account of the between-study variance in our find-
ings. All analyses were performed on R3.2 with the meta
and metafor packages. We considered P values < 0.05 to
be statistically significant. When outcomes were dichot-
omous, we used unadjusted odds ratio (OR) for non-RCTs
(cohort and case-control studies); when outcomes were
continuous, we used mean difference (MD); each was pro-
vided with 95 % confidence intervals (95 % CIs).
We followed the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions [22]
in assessing the impact of heterogeneity. In general, we
interpreted an I2 value > 60 % as having substantial hetero-
geneity and meta analyses cannot be done; an I2 value ≤
40 % would suggest little concern about statistical hetero-
geneity. If data was sufficient, we would undertake the fol-
lowing subgroup analyses for each comparison:
1) Severity of disease: based on SAPS II [21] at admission.
Studies were classified into less severe group when a
mean of SAPS II < 60 and more severe group when a
mean of SAPS II ≥ 60. Participants in more severe
group were considered to have more severe disease
than those in less severe group. In addition, disease
severity could also be assessed by Sequential Organ
Failure Assessment (SOFA) [26] and PaO2/FiO2.
2) Causes of the immunocompromised status.
Results
We retrieved 3359 records from the electronic database
searches (Fig. 1 for a flow diagram of studies identified).
Thirteen non-RCTs [17, 20, 27–37] met all of the inclusion
criteria with a detailed description of each available in
Table 1. There were one prospective cohort study [20], three
retrospective cohort studies [28, 31, 34] and nine retrospect-
ive case-control studies [17, 27, 29, 30, 32, 33, 35–37]. A
total of 2552 patients were included in our final ana-
lysis. Sample size in each study ranged between 15 and
1302. One study included children with a mean age of
9 years old [33]. The rest recruited adults with age
ranged from 17 to 82. All studies met the diagnosis cri-
teria for acute respiratory failure and immunocomprom-
ised status. Main types of ARF included adult respiratory
distress syndrome/acute lung injury (ARDS/ALI), infec-
tious pneumonia, chronic obstructive pulmonary disease
(COPD), and pulmonary edema. Causes of patients’ im-
munocompromised status included AIDS, hematologic
malignancies, solid tumors, bone marrow transplantation
(BMT), chemotherapy and receipts of immunosuppressive
medications. All included studies compared NIV with
IMV as the first mechanical ventilation technique in im-
munocompromised patients with ARF. Settings in the
NIV group were as follows: (1) Ventilation modes: two
studies [27, 32] used continuous positive airway pressure
(CPAP) ventilation only; three [33, 34, 36] solely used
bilevel positive airway pressure (BiPAP); another five
[17, 20, 28, 30, 37] solely used pressure support ventilation
(PSV); another one [31] used both CPAP and Bi-PAP; no
description was given in the remaining studies. (2) Inter-
faces: full face mask, face mask, nasal mask or helmet. (3)
Duration and continuity: eight studies applied NIV con-
tinuously for the first 24 h in the NIV group. Four studies
didn’t report the duration of mechanical ventilation. (4)
Positive End Expiratory Pressure (PEEP): in most studies,
PEEP ranged between 3–10 cmH2O, adjusted with venti-
lation flow, pressure support and other settings to achieve
a proper clinical outcome, including a pulse oximetry
oxyhemoglobin saturation ≥ 95 %, an oxygen saturation ≥
90 %, FiO2 ≤ 0.6, an exhaled tidal volume of 8 to 10 ml/
kg or a respiratory rate ≤ 25 breaths/min. A portion of pa-
tients who initially received NIV switched to IMV due to
NIV failure, with a mean intubation rate of 49.5 %, ranging
from 25.8 to 78.3 %. For the IMV group, however, only
three studies gave a description for ventilation settings,
two of which used volume-controlled ventilation, the
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other used pressure controlled ventilation. Supportive
treatments were described in three studies, including
use of antimicrobial agents, diuretics, bronchodilators,
granulocyte-colony stimulating factor, dialysis, and
parenteral nutrition, etc.
Five studies were excluded for the fact that there was
no or improper invasive mechanical ventilation group
set as control group among these studies [38–42]. An-
other common reason was that invasive mechanical ven-
tilation was not studied as a comparison but rather an
outcome of the non-invasive ventilation [43, 44]. Two
more studies were excluded since attempts to obtain ori-
ginal data from the author concerning subgroup data
were unsuccessful [45, 46]. Two studies were excluded
since less than 85 % of participants who were diagnosed
as ARF on admission [47, 48]. One was excluded be-
cause participants were not restricted within patients
with ARF [49]. In addition, baseline of PaO2/FiO2)
was higher than 300, which has already exceeded the
upper limit of current definition of ARF. One was
excluded since it used a different definition of 30-
day mortality [50].
Study quality
We used the adapted Newcastle Ottawa Scale to assess
the risk bias in cohort/case-control studies in our re-
view, as described in the Methods section. The four co-
hort studies scored between 7 and 8 (out of a 9 points),
with one study at low risk of bias and three at medium
risk. The other nine case-control studies scored between
3 and 6 (out of 8 points), all assessed as high risk of bias
but one as medium (see Additional file 1).
We defined main primary outcomes to assess the qual-
ity of evidence using the GRADE methodology (Table 2).
The main factor that may downgrade the levels of qual-
ity was the non-RCT study design in all included studies,
which share the inherent limitations of the design and
implementation compared to RCTs. Another factor was
the inconsistency of results across the small number of
included trials. The substantial heterogeneity may be
3024 records identified 
through database searching
484 additional records identified 
through other sources
3359 records after duplicates removed
3359 records screened 3333 records excluded
26 full-text articles assessed 
for eligibility
13 full-text articles excluded
13 studies included in 
qualitative synthesis
13 studies included in quantitative synthesis (meta-analysis), available for the 
following outcomes:
Mortality in hospital 7
Mortality in ICU 9
30-day mortality 2
Duration of hospitalization 3
Duration of ICU stay 4
Nosocomial infections 4
Duration of mechanical ventilation 3
Fig. 1 Study flow diagram
Wang et al. BMC Pulmonary Medicine  (2016) 16:129 Page 4 of 14
Table 1 Characteristics of the included studies
Study Study design Settings Sample size (NIV/IMV) Cause of immunodeficiency SAPS II (SD orrange) Number of NIV patients
that switched to IMV (%)
Outcomes
Azoulay 2001 Cohort, single-
centered
France, ICU 96 (48/48) Hematologic malignancy
or solid tumors
NIV: 47 (38–60) Not specified 1. 30-day mortality
IMV: 44.5 (36–59) 2. Nosocomial infections
Azoulay 2003 Case-control,
single-centered
France, ICU 15 (7/8) Hematological malignancy NS 4 (57.1) 1. Mortality (in ICU)
Azoulay 2004 Case-control,
single-centered
France, ICU 148 (79/69) Hematological malignancy,
allogeneic BMT, solid tumors,
chemotherapy
NS 45 (57.0) 1. Mortality (in hospital)
B-M 2013 Case-control,
single-centered
Spain, ICU 41 (35/6) Hematological malignancy 63 (18) 14 (40.0) 1. Mortality (in hospital)
2. Mortality (in ICU)
3. Duration of ICU stay
4. Duration of hospitalization
5. Nosocomial infections
6. Duration of mechanical ventilation
Confalonieri 2002 Cohort, single-
centered
Italy, ICU 48 (24/24) AIDS NIV: 37 (9) 8 (33.0) 1. Mortality (in ICU)
IMV: 38 (5) 2. Duration of ICU stay
3. Duration of hospitalization
4. Nosocomial infections
5. Duration of mechanical ventilation
Depuydt 2004 Cohort, single-
centered
Belgium, ICU 78 (26/52) Hematological malignancy
and allogeneic BMT
NIV: 46 18 (69.2) 1. Mortality (in hospital)
IMV: 46




91 (24/67) Hematological malignancy
and allogeneic BMT
NIV: 52 (15) 18 (75.0) 1. Mortality (in ICU)
IMV: 65 (18) 2. Mortality (in hospital)
3. Duration of ICU stay
Gachot 1992 Case-control,
single-centered
France, ICU 45 (36/9) AIDS NS 11 (30.6) 1. Mortality (in ICU)
2. Mortality (in hospital)
Gristina 2011 Case-control,
multicenter
Italy, ICU 1302 (274/1028) Hematologic malignancy NIV: 49 (16) 126 (46.0) 1. Mortality (in ICU)
IMV: 58 (18) 2. Mortality (in hospital)
3. Duration of ICU stay
4. Duration of hospitalization
















Table 1 Characteristics of the included studies (Continued)
Molina 2012 Case-control,
multicenter
Spain, ICU 300 (131/169) Hematological malignancy
and BMT
NS 79 (60.3) 1. Mortality (in ICU)
Pancera 2008 Case-control,
single-centered
Italy, PICU 239 (120/119) Hematologic malignancy
or solid tumors




Austria, ICU 82 (35/47) Autologous or allogeneic
BMT for hematological
malignancies




Turkey, ICU 67 (46/21) Hematological malignancies NS 36 (78.3) 1. Mortality (in ICU)
Abbreviations: AIDS acquired immune deficiency syndrome; BMT bone marrow transplantation; ICU Intensive Care Unit; PICU Pediatric Intensive Care Unit; USA United States of America; NIV Noninvasive mechanical















Table 2 Summary of main findings
Patient or population: Immunocompromised patients with acute respiratory failure
Setting: ICUs, General medical units.
Intervention: Noninvasive mechanical ventilation
Comparison: Invasive mechanical ventilation





Mortality in hospital 624 per 1000 416 per 1000 (276 to 570) OR 0.43 (0.23 to 0.80) 1787 (7 observational studies) ⨁◯◯◯ VERY LOWb
Mortality in hospital- Less severe
subgroup
584 per 1000 496 per 1000 (431 to 558) OR 0.70 (0.54 to 0.90) 1380 (2 observational studies) ⨁⨁◯◯ LOW
Mortality in ICU 549 per 1000 339 per 1000 (226 to 464) OR 0.42 (0.24 to 0.71) 2148 (9 observational studies) ⨁⨁◯◯ LOWb,c
Mortality in ICU- AIDS subgroup 576 per 1000 230 per 1000 (98 to 440) OR 0.22 (0.08 to 0.58) 93 (2 observational studies) ⨁⨁⨁◯ MODERATEc
Mortality in ICU-Hematological
malignancy and BMT subgroup
543 per 1000 443 per 1000 (348 to 543) OR 0.67 (0.45 to 1.00) 1816 (6 observational studies) ⨁◯◯◯ VERY LOWd
Mortality in ICU Hematological
malignancy and solid tumors
subgroup
613 per 1000 222 per 1000 (137 to 337) OR 0.18 (0.10 to 0.32) 239 (1 observational study) ⨁⨁◯◯ LOW
30-day mortality 749 per 1000 503 per 1000 (396 to 616) OR 0.34 (0.22 to 0.54) 335 (2 observational studies) ⨁⨁⨁◯ MODERATEc
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
CI confidence interval; OR odds ratio; MD mean difference
aThe risk in the intervention group (and its 95 % confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95 % CI)
bSubstantial heterogeneity may be due to methodological variations among studies and clinical variations among participants
cUpgraded due to large sample size and/or large outcome events















attributed to methodological variations among studies
and clinical variations among participants. Although the
definition of ARF fulfilled the inclusion criteria, substan-
tial heterogeneity existed in the types of ARF. The pau-
city of studies made us unable to conduct subgroup
analyses or meta regression analyses to explore causes of
such heterogeneity. Few studies reported estimates of ef-
fect after adjustment by multiple variables. In addition,
some included studies had small sample sizes, which
made them less representative of the exposed popula-
tion. There were also factors that upgraded the levels of
quality for the outcome (30-day mortality) due to rela-
tively large outcome events (Table 2).
Primary outcomes
We found a significantly lower mortality in hospital
in NIV compared to IMV (OR 0.43, 95 % CI 0.23 to 0.80,
P value = 0.007), but the heterogeneity was substantial (I2
statistic = 62 %). Subgroup analysis of less severe group
showed similar result (OR 0.70, 95%CI 0.54 to 0.90,
P value = 0.007; I2statistic = 0 %, Fig. 2). One study
(Depuydt 2010) [34], with overlapped mean of SAPS II
(52–65), was allocated in the more severe subgroup due
to a substantially lower mean value of PaO2/FiO2 and
relatively higher SOFA score than other studies. In AIDS
subgroup, only one study was included, which showed
NIV significantly reduced the mortality in hospital (OR
0.17, 95 % CI 0.03 to 0.81, P value = 0.03). In addition,
multivariate logistic regression analysis reported in one
study (Gristina 2011) [17], after adjustments for all available
demographic characteristics and clinical variables, an initial
NIV was associated with a significantly lower mortality in
hospital (OR 0.73, 95 % CI 0.53 to 1.00, P value = 0.05).
As for mortality in ICU, meta-analysis was not pos-
sible in both overall and subgroup analysis of disease se-
verity due to substantial heterogeneity (overall analysis:
I2 statistic = 72 %). Subgroup analysis of causes of im-
munodeficiency showed that NIV was associated with a
significant reduction of mortality in ICU in all subgroups,
AIDS subgroup (OR 0.20, 95 % CI 0.07 to 0.54, P value =
0.001, I2 statistic = 0 %, Fig. 3), hematological malignancy
and BMT subgroup (OR 0.67, 95 % CI 0.45 to 1.00, P
value = 0.05, I2 statistic = 34 %), and hematological malig-
nancy and solid tumors subgroup (OR 0.18, 95 % CI 0.10
to 0.32, P value < 0.00001).
The meta-analysis of two studies showed a statistically
significant reduction of 30-day mortality between NIV ver-
sus IMV (OR 0.34, 95 % CI 0.22 to 0.54, P value < 0.0001,
I2 statistic = 0 %, Fig. 4). Subgroup analysis of disease se-
verity was not possible due to lacking of SAPS II data.
Both studies were in the haematological malignancy and
solid tumors subgroup, thus, significantly favour NIV. One
study (Azoulay 2001) [28] reported a multivariate logistic
regression analysis, showing that the probability of 30-day
mortality was significantly decreased in NIV compared with
IMV, with an odds ratio of 0.31 (95 % CI 0.12 to 0.82).
Secondary outcomes
Four studies revealed no significant difference in the rate
of nosocomial infections in patients on NIV in compari-
son with IMV. Similar results were shown in subgroup
analysis of disease severity. Significant difference was
found only in the hematological malignancy and BMT
subgroup favoring NIV (OR 0.58, 95 % CI 0.36 to 0.93, P
value = 0.03, I2 statistic = 0 %, Fig. 5).
Duration of mechanical ventilation was reported in
three studies, but data couldn’t be pooled in the meta-
analysis due to substantial heterogeneity (overall I2 statis-
tic = 98 %). One study (Confalonieri 2002) [20] reported a
statistically significant shortening of mechanical ventila-
tion favoring NIV versus IMV (MD± SD: 6 ± 2 versus 7 ±
1 days, P value = 0.034). Another (Gristina 2011) [17]
Fig. 2 Mortality in hospital by disease severity. CI confidence interval, I2 percentage of total variation across studies from between-study hetero-
geneity rather than chance. Vertical solid line null effect, Vertical dotted line overall effect
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reported that the mean duration of mechanical ventilation
was 4 days (SD 4 days) in NIV group, compared to 11 days
(SD 4 days) in IMV group (P value < 0.0001). The rest
(B-M 2013) [36] revealed no difference among the
two groups (P value = 0.08).
Duration of ICU stay was reported in four studies.
Overall and subgroup analyses of cause of immunodefi-
ciency were not possible due to substantial heterogeneity
(overall: I2 statistic = 62 %). In less severe subgroup, we
found a statistically significant shortening of ICU stay in
favor of NIV (MD −3.00 days; 95 % CI −4.27, −1.73 days,
P value < 0.00001, I2 statistic = 0 %, Fig. 6).
Duration of hospitalization could only be pooled in
the subgroup analysis of cause of immunodeficiency.
One study (Confalonieri 2002) [20] in AIDS subgroup
reported a statistically significant shortening of mechan-
ical ventilation favoring NIV versus IMV (MD ± SD: 13
± 5 versus 24 ± 17 days, P value = 0.004, Fig. 7).
Discussion
To our knowledge this is the first systematic review aim-
ing at compilation of the clinical evidence of the effect
of NIV compared to IMV on ARF in immunocomprom-
ised patients. The overall evidence we obtained supports
NIV over IMV in treating ARF in certain group of
immunocompromised patients. Compared to IMV, NIV
was shown to significantly reduce mortality in overall
analysis, and mortality and duration of hospitalization/
ICU stay in less severe (mainly reflected by SAPS II < 60),
AIDS, hematological malignancy subgroups.
Compared with IMV, NIV is more frequently associated
with minor complications because NIV avoids endotracheal
tube or tracheostomy hence leaves the upper airway intact,
and preserves airway defense mechanisms. Various compli-
cations directly related to the process of intubation and
IMV such as nosocomial pneumonia, aspiration of gastric
contents, ventilator-associated events, trauma of the teeth,
hypopharynx, esophagus, larynx, and trachea could thus be
avoided by application of NIV [19, 51, 52]. These complica-
tions are far more common in patients who are immuno-
compromised or critically ill. In addition, NIV causes less
mask-related discomfort, unrecognized patient-ventilator
asynchrony due to leaks, and milder gastric insufflations.
At the meantime, NIV achieves the same physiological ben-
efits of reduced work of breathing and improved gas ex-
change for certain groups of patients [53].
Although NIV was recommended as the first-line strat-
egy for immunocompromised patients with ARF by guide-
lines in several countries [11, 54], our study along with
several previous studies showed that NIV might not be
Fig. 4 30-day mortality
Fig. 3 Mortality in ICU by cause of immunodeficiency
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the appropriate choice for all immunocompromised
patients [15–17]. NIV has been stated by German and
Canadian guidelines as the first-line treatment, with differ-
ent recommendation levels, for immunocompromised pa-
tients with ARF [11, 54], though they were based on the
same two RCTs [41, 55]. However, the control against
NIV in both RCTs was standard oxygen therapy instead of
IMV. In addition, participants in both RCTs were less se-
vere than those in our review. The mean SAPS II in Hil-
bert 2001 [41] was no more than 45, and mean SAPS in
Antonelli 2000 [55] was 13. Our result, along with several
other reviews raised new puzzles and debates for NIV as
the first-line approach for immunocompromised patients
with ARF [16, 56]. We make the speculation that
spectrum of choice for oxygen supplement strategy varies
among standard oxygen therapy, NIV or IMV depending
on different disease severity, and NIV or standard oxygen
therapy should be applied in less severe patients. For the
more severe patients, however, the choice might be lim-
ited within NIV or IMV. Our review showed that even in
relatively more severe patients (45 < SAPS II < 60) than
those in the two RCTs, NIV still showed significant advan-
tages against IMV.
As is shown in our analysis, effects of NIV on patients
vary with different levels of disease severity, different
causes of immunocompromised status and types of ARF.
Strict patient selection is of critical importance for the
effect of NIV and other oxygen therapies. As for disease
severity, our analysis showed NIV had clear advantage in
less severe patients (mainly reflected by SAPS II < 60).
For cause of immunodeficiency, NIV showed great advan-
tage over IMV among AIDS patients in reducing mortality
in both hospital and ICU, duration of both hospital and
ICU stay, and also duration of mechanical ventilation.
NIV was also related to better prognosis in hematological
malignancies and BMT patients. Data available, though
weak, also favored NIV in patients with solid tumors. One
systematic review by Laura et al. [57] included thirteen
studies to examine the effect of initial NIV versus IMV in
hematological patients with ARF. Eight studies of which
Fig. 6 Duration of ICU stay by disease severity. SD standard deviation
Fig. 5 Nosocomial infections by cause of immunodeficiency
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were also included in our review. NIV is associated with a
lower risk of death in hematological patients (RR 0.74,
95 % CI 0.65 to 0.84, p < 0.0001), which was similar with
our results. Unfortunately, there was little evidence show-
ing the effects of NIV on different types of ARF due to
lacking of data. Two studies [17, 38] showed poor progno-
sis of NIV in ALI/ARDS. NIV was strongly recommended
as the first-line approach for acute exacerbation of chronic
obstructive pulmonary disease (AECOPD), facilitation of
weaning/extubation in patients with COPD and cardio-
genic pulmonary edema in immunocompetent patients
[11, 54]. The criteria between immunocompetent and im-
munocompromised patients are not identical, but similar.
We expect similar efficacy of NIV in immunocomprom-
ised patients with these types of ARF. In addition, another
review [58] emphasized the importance of patient selec-
tion and suggested both absolute and relative situations in
which NIV is contraindicated. However, additional studies,
especially randomized controlled trials, are needed to ex-
plore the possible benefits and/or risks of NIV in these
groups of patients.
Considering that our analysis showed NIV reduced
mortality in less severe patients, early recognition and
prediction of NIV failure and timely initiation of IMV
are of great importance for patients’ overall survival, es-
pecially for more severe patients. Laura et al. [57]
showed that failure of NIV might worsen the prognosis,
mainly in less severe patients. Predictors of failure of
NIV in immunocompromised patients were summarised
in one review [16], including higher illness severity at
baseline reflected by SAPS II, higher respiratory rate
under NIV, later initiation of NIV after ICU admission,
need for vasopressors, renal replacement therapy, and
presence of ALI/ARDS. Criteria used for NIV discontinu-
ation and endotracheal intubation in immunocomprom-
ised patients were also suggested, including persistent
dyspnea, severe hemodynamic or electrocardiographic in-
stability, etc. The cut-off point for switching NIV to IMV
in immunocompromised patients is still a puzzling issue
which calls for more high-qualified studies [59].
The presence of patients who initially received NIV
switched to IMV due to NIV failure did not substantially
change our overall results and final conclusion. Almost
all included studies (12 out of 13, excluding one study
where the rate was not specified) reported such switch-
ing to IMV after initial NIV treatment. The mean intub-
ation rate after initial NIV treatment was 49.5 %, greater
than or equal to 50 % in seven studies and lower than
50 % in five studies (Table 1). We did a subgroup meta-
analysis based on intubation rate in NIV group (Additional
file 1), which showed that when intubation rate was lower
than 50 %, NIV was more favorable in terms of mortality
in ICU, 30-day mortality, duration of ICU stay as well as
nosocomial infections. No significant difference was found
between the NIV and IMV groups in terms of mortality in
hospital, mortality in ICU and duration of ICU stay when
intubation rate was greater than or equal to 50 %. It is
thus reasonable to deduct that the final analysis results
would be in even more favour of NIV if the overall intub-
ation rate of all the studies included are lower than 50 %.
In addition, a research where NIV patients are kept from
switching to IMV once their conditions worsen would be
unethical and in turn, impractical.
The major limitation of the present systematic review
was that all included studies were exclusively observational.
Given to the limitations of current data, RCTs of good
methodological design are needed to address the effect of
NIV versus IMV in treating acute respiratory failure in im-
munocompromised patients. Researchers should consider
RCTs with a sample size large enough to demonstrate a
meaningful result. Although it would be impossible to con-
duct double-blinded trials in the future due to the nature of
intervention, it would be important to undertake blind as-
sessment of the participants to ensure quality of the trials
and minimize the risk of bias, with well classified causes of
ARF and immunocompromised status and well stratified
Fig. 7 Duration of hospitalization by cause of immunodeficiency
Wang et al. BMC Pulmonary Medicine  (2016) 16:129 Page 11 of 14
disease severity. Settings of intervention such as time be-
tween onset of acute respiratory failure and ICU admission,
clear indications and contra-indications for NIV and or
high flow oxygen therapy, type of interface and equipment
use, strict NIV and high flow oxygen use protocol, early
recognition of NIV or high flow oxygen failure, clear indi-
cations of intubation and invasive protective mechanical
ventilation should also be well matched [56]. In place of
RCTs, we suggest well-conducted observational studies,
such as strictly matched prospective cohort studies.
Conclusions
The overall evidence we obtained from 2552 immuno-
compromised patients with ARF shows NIV was associ-
ated with a significant lower mortality rates, especially in
less severe patients and those who was immunosuppressed
by AIDS, haematological malignancies and bone marrow
transplant. For more severe patients, however, NIV didn’t
show clear advantages over IMV. The advantages of NIV
were also shown in reducing duration of hospitalization
and ICU stay, as well as rates of nosocomial infection. Fu-
ture studies need to be methodologically sound and in-
clude patients immunocompromised by other causes such
as chemotherapy and receipt of glucocorticoids.
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